<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Overexpression of cyclooxygenase-2 (Cox-2) is thought to exert antiapoptotic effects in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Here we show that the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor p53 upregulated Cox-2 in esophageal and <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cell lines by inducing the binding of nuclear factor-kappaB (NF-kappaB) to its response element in the COX-2 promoter </plain></SENT>
<SENT sid="2" pm="."><plain>Inhibition of NF-kappaB prevented p53 induction of Cox-2 expression </plain></SENT>
<SENT sid="3" pm="."><plain>Cooperation between p53 and NF-kappaB was required for activation of COX-2 promoter in response to daunomycin, a DNA-damaging agent </plain></SENT>
<SENT sid="4" pm="."><plain>Pharmacological inhibition of Cox-2 enhanced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in response to daunomycin, in particular in cells containing active p53 </plain></SENT>
<SENT sid="5" pm="."><plain>In <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e>, there was a correlation between Cox-2 expression and <z:mp ids='MP_0002169'>wild-type</z:mp> TP53 in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (BE) and in <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, but not in <z:hpo ids='HP_0002860'>squamous cell carcinoma</z:hpo> (P&lt;0.01) </plain></SENT>
<SENT sid="6" pm="."><plain>These results suggest that p53 and NF-kappaB cooperate in upregulating Cox-2 expression, promoting cell survival in inflammatory precursor lesions such as BE </plain></SENT>
</text></document>